POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Axsome Therapeutics (NASDAQ:AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05, ...

IGC Pharma, Inc. (NYSE:IGC) shares made small progress Wednesday, on word its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Dec 30 (Reuters) - Axsome Therapeutics (AXSM.O), opens new tab said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease ...

Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)ACCORD-2 Phase 3 ...

Axsome (AXSM) said the results support the efficacy and safety of AXS-05 in the treatment of agitation in Alzheimer's patients. The company plans to submit a New Drug Application to the FDA for ...

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared ...